Research Article
Outcomes of Universal Access to Antiretroviral Therapy (ART) in Georgia
Table 1
Baseline characteristics.
| | Characteristic | n = 752 |
| | Age, median years (IQR) | 37 (33–43) | | Gender, n (%) | | | Male | 570 (75.8) | | Female | 182 (24.2) | | Mode of transmission, n (%) | | | Injection drug use | 454 (60.4) | | Heterosexual contact | 265 (35.2) | | Male-to-male sex | 17 (2.3) | | Blood recipient | 6 (0.8) | | Other/not identified | 10 (1.3) | | CD4 cell count, median cells/mm3 (IQR) | 141 (76–208) | | HIV RNA load, median log10 copies/ml (IQR) | 5.4 (4.8–5.8) | | AIDS defining illness, n (%) | 446 (59.3) | | Malignancy, n (%) | 22 (2.9) | | Liver related diseases, n (%) | | | Anti-HCV+ | 397 (52.8) | | HbsAg+ | 63 (8.4) | | Anti-HCV+/HbsAg+ | 47 (6.3) | | Cirrhosis | 104 (13.8) | | Initial HAART regimen, n (%) | | | AZT + 3TC + EFV | 310 (41.2) | | AZT + 3TC + NVP | 86 (11.4) | | AZT + 3TC + LPV/r | 3 (0.4) | | ABC + 3TC + EFV | 187 (24.9) | | ABC + 3TC + NVP | 15 (2.0) | | ABC + 3TC + LPV/r | 2 (0.3) | | TDF + FTC + EFV | 9 (1.2) | | TDF + FTC + NVP | 2 (0.3) | | d4T + 3TC + EFV | 126 (16.7) | | d4T + 3TC + NVP | 12 (1.6) |
|
|
